Sanofi: FDA Approves Fluzone High-Dose Quadrivalent for Adults 65 and Older
November 04 2019 - 06:14PM
Dow Jones News
By Stephen Nakrosis
Sanofi on Monday said the U.S. Food and Drug Administration
approved a supplemental Biologics License Application for its
Fluzone influenza vaccine for use by adults 65 and older.
The application was for the company's Fluzone High-Dose
Quadrivalent (Influenza Vaccine), Sanofi said.
"Fluzone High-Dose Quadrivalent is given to people 65 years of
age and older to help prevent influenza disease caused by influenza
A and B strains contained in the vaccine," the company said.
David Loew, Sanofi Executive Vice President and head of Sanofi
Pasteur, said, "We are excited to build upon the success of
trivalent Fluzone High-Dose with this FDA approval to expand
protection for an additional B strain. We have submitted filings
with additional regulatory bodies outside the U.S. and anticipate
approval in the European Union next spring."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 04, 2019 17:59 ET (22:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2023 to Mar 2024